These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25781030)

  • 21. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine.
    Mouton C; Calderon J; Janvier G; Vergnes MC
    Thromb Res; 2003; 111(4-5):273-9. PubMed ID: 14693175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Porous dynamic covalent polymers as promising reversal agents for heparin anticoagulants.
    Zong Y; Xu YY; Wu Y; Liu Y; Li Q; Lin F; Yu SB; Wang H; Zhou W; Sun XW; Zhang DW; Li ZT
    J Mater Chem B; 2022 May; 10(17):3268-3276. PubMed ID: 35357392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice.
    Swieton J; Miklosz J; Yusa SI; Szczubialka K; Pawlak D; Mogielnicki A; Kalaska B
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonism of SR 90107A/Org 31540-induced bleeding by protamine sulfate in rats and mice.
    Bernat A; Hoffmann P; Herbert JM
    Thromb Haemost; 1996 Nov; 76(5):715-9. PubMed ID: 8950779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.
    Chang LC; Liang JF; Lee HF; Lee LM; Yang VC
    AAPS PharmSci; 2001; 3(3):E18. PubMed ID: 11741269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate.
    Racanelli A; Fareed J
    Thromb Res; 1992 Nov; 68(3):211-22. PubMed ID: 1471069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
    Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
    Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chitosan derivatives as novel potential heparin reversal agents.
    Kamiński K; Szczubiałka K; Zazakowny K; Lach R; Nowakowska M
    J Med Chem; 2010 May; 53(10):4141-7. PubMed ID: 20423087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivation of heparin by cationically modified chitosan.
    Lorkowska-Zawicka B; Kamiński K; Ciejka J; Szczubiałka K; Białas M; Okoń K; Adamek D; Nowakowska M; Jawień J; Olszanecki R; Korbut R
    Mar Drugs; 2014 Jun; 12(7):3953-69. PubMed ID: 24983639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride.
    Andrassy K; Eschenfelder V; Weber E
    Thromb Res; 1994 Jan; 73(2):85-93. PubMed ID: 8171416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orally administered heparins prevent arterial thrombosis in a rat model.
    Pinel C; Wice SM; Hiebert LM
    Thromb Haemost; 2004 May; 91(5):919-26. PubMed ID: 15116252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis.
    Silver PJ; Broughton R; Bouthillier J; Quinn TA; Wallace AM; Weishaar RE
    Thromb Res; 1998 Aug; 91(3):143-50. PubMed ID: 9733158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
    Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
    Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of heparin antagonists with focused biological activity.
    Shenoy S; Harris RB; Sobel M
    Curr Pharm Des; 1999 Dec; 5(12):965-86. PubMed ID: 10607857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine.
    Doutremépuich C; Bonini F; Toulemonde F; Bertrand H; Bayrou B; Quilichini R
    Semin Thromb Hemost; 1985 Jul; 11(3):318-22. PubMed ID: 4048954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversible block of the calcium release channel/ryanodine receptor by protamine, a heparin antidote.
    Koulen P; Ehrlich BE
    Mol Biol Cell; 2000 Jul; 11(7):2213-9. PubMed ID: 10888663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
    Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
    J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.